Business context and reporting period
Roper Industries, Inc. (the registrant named in the filing; metadata identifies Roper Technologies Inc.) filed this unaudited Form 10-Q for the quarter ended March 31, 2011. The diversified company operates in Industrial Technology, Energy Systems & Controls, Medical & Scientific Imaging, and RF Technology. Comparisons are with Q1 2010 unless noted.
Financial performance and position
| Metric | Q1 2011 | Q1 2010 / comparison |
|---|---|---|
| Net sales | $645.3 million | $534.4 million; up 20.7% |
| Gross profit / margin | $350.1 million / 54.3% | $279.6 million / 52.3% |
| Operating income / margin | $142.0 million / 22.0% | $100.7 million / 18.8% |
| Net earnings | $89.0 million | $59.7 million |
| Diluted EPS | $0.91 | $0.62 |
| Operating cash flow | $86.6 million | $95.1 million |
| Cash and equivalents | $261.4 million | $270.4 million at Dec. 31, 2010 |
| Total debt | $1.242 billion | $1.341 billion at Dec. 31, 2010 |
| Net debt / total net capital | 25.4% | 28.0% at Dec. 31, 2010 |
Revenue grew 17% organically and 4% from 2010 acquisitions. All segments increased sales: Industrial Technology 25.6%, Energy Systems & Controls 22.7%, Medical & Scientific Imaging 11.5%, and RF Technology 22.8%. Segment operating profit rose 38.3% overall; margins improved in each segment. Q1 net orders increased 24% to $702.3 million, and backlog rose 43% year over year to $851.2 million.
Operating cash flow declined 8.9%, mainly because of higher receivables and inventory tied to the timing of sales and orders, partly offset by higher earnings. Investing used $9.0 million, primarily for capital expenditures; financing used $96.1 million, principally for debt repayments and dividends. Working capital was $342.5 million, versus $281.4 million at year-end. The company reported $247 million of cash at foreign subsidiaries, considered permanently reinvested. It was in compliance with debt covenants.
Material changes and unusual items
- Growth and margin expansion reflected broad-based demand, operating leverage, and favorable product mix. Medical & Scientific Imaging’s year-over-year gross-margin comparison also benefited from a $3.9 million inventory step-up charge in Q1 2010.
- Interest expense increased $0.5 million to $16.7 million, as higher average debt balances were partly offset by lower average rates. The effective tax rate was 29.4%, versus 29.7%.
- Foreign-currency translation increased comprehensive earnings by $37.2 million; the filing describes a $38.9 million increase in net assets from currency movements, including $20.7 million related to goodwill, which does not directly affect expected cash flows.
- The company adopted revised revenue-recognition guidance on January 1, 2011; the impact was immaterial. Q1 revenue recognized using percentage-of-completion accounting was $29.1 million, with $158.1 million related to unfinished contracts not yet recognized.
Outlook, risks, and contingencies
Management expected existing and recently acquired businesses to generate positive operating cash flow and support debt reduction, but said the pace would depend on operating performance and acquisition financing needs. Capital spending for the rest of 2011 was expected to be comparable to prior years as a percentage of sales. No specific earnings or revenue guidance was provided. Management cited continued acquisition opportunities, while noting timing and effects could not be estimated.
Risks include economic and geopolitical uncertainty, acquisition integration and liabilities, indebtedness and interest rates, foreign exchange, cyclical markets, customer concentration, raw-material costs, competition, product liability and warranty exposure, government contracts, environmental matters, and potential impairment of substantial goodwill and intangible assets. Ordinary-course litigation was not expected by management to materially harm results, but potential asbestos-related liability could not be determined. The warranty accrual was $7.6 million. A 1% interest-rate increase was estimated to raise annual pretax interest costs by approximately $6.5 million.
Important facts for investors to verify
- Confirm the entity-name mapping: the filing identifies the registrant as Roper Industries, Inc., while the request metadata says Roper Technologies Inc.
- Assess whether strong orders and backlog convert to revenue and cash, particularly given the quarter’s working-capital use.
- Review debt maturities, variable-rate exposure, and the effect of the $500 million interest-rate swap; verify the company’s debt-reduction assumptions.
- Evaluate the concentration of cash overseas and the potential tax cost of repatriation.
- Monitor acquisition activity, goodwill and intangible-asset exposure, and the uncertainty around asbestos claims and other contingencies.